<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84057">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02009449</url>
  </required_header>
  <id_info>
    <org_study_id>AM0010-001</org_study_id>
    <nct_id>NCT02009449</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARMO BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARMO BioSciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, open-label, dose escalation study to evaluate the safety and
      tolerability of AM0010 in patients with advanced solid tumors, dosed daily subcutaneously.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability as measured by incidence of adverse events</measure>
    <time_frame>approximately 4 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters</measure>
    <time_frame>Approximately 4 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PK parameters including the serum trough concentration (Minimal Drug Concentration (Cmin)), the maximal drug concentration (Cmax), area under the curve of serum concentration over time (Area Under the Curve/ AUC), and half-life (tÂ½).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor burden measured by volumetric Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) according to immune-related response criteria (irRC)</measure>
    <time_frame>approxinatetly 4 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression in bone by bone scintigraphy according to Prostate Cancer Working Group 2 (PCWG2) for patients with metastatic castration resistant prostate cancer (CRPC)</measure>
    <time_frame>approximatley 4 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-AM0010 antibody formation</measure>
    <time_frame>approximately 4 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Melanoma</condition>
  <condition>Prostate Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (1 ug/kg) - Daily subcutaneous (SC) injections of AM0010 for up to 4 cycles of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (2.5 ug/kg) - Daily subcutaneous injections of AM0010 for up to 4 cycles of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (5 ug/kg) - Daily subcutaneous injections of AM0010 for up to 4 cycles of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (10 ug/kg) - Daily subcutaneous injections of AM0010 for up to 4 cycles of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (20 ug/kg) - Daily subcutaneous injections of AM0010 for up to 4 cycles of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>at least 15 patients will be dosed  with AM0010</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM0010</intervention_name>
    <description>Daily subcutaneous injections of AM0010 up to 4 cycles of 28 days</description>
    <arm_group_label>Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>Dose Escalation Cohort 3</arm_group_label>
    <arm_group_label>Dose Escalation Cohort 4</arm_group_label>
    <arm_group_label>Dose Escalation Cohort 5</arm_group_label>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <other_name>PEGylated recombinant human Interleukin-10</other_name>
    <other_name>PEG-rHuIL-10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid tumor, limited to melanoma, hormone refractory prostate cancer,
             ovarian cancer,  renal cell carcinoma, colorectal carcinoma (CRC), pancreatic
             carcinoma or non-small cell lung carcinoma (NSCLC) that is refractory to, intolerant
             of, for which no standard of therapy is available or where the patient refuses
             existing therapies

          -  Measurable or evaluable disease according to irRC or bone metastatic disease
             evaluable by Prostate Cancer Working Group 2 criteria (PCWG2) for
             castration-resistant prostate cancer (CRPC)

          -  At least 18 years of age

          -  Performance Status of 0 or 1

          -  Adequate organ function

        Exclusion Criteria:

          -  Hematologic malignancies

          -  Pregnant or lactating

          -  Present or history of neurological disorders such as Multiple Sclerosis and Guillain
             Barre or inflammatory central nervous system/peripheral nervous system (CNS/PNS)
             disorders

          -  Myocardial infarction within the last 6 months

          -  Unstable angina, or unstable cardiac arrhythmia requiring medication

          -  Surgery within the last 28 days

          -  Systemic fungal, bacterial, viral, or other infection

          -  History of bleeding diathesis within the last 6 months

          -  Positive for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Oft, MD</last_name>
    <role>Study Director</role>
    <affiliation>ARMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caryn Kata</last_name>
      <phone>617-582-7603</phone>
    </contact>
    <investigator>
      <last_name>Patrick Ott, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Autio, MD</last_name>
      <phone>646-888-3359</phone>
    </contact>
    <investigator>
      <last_name>Karen Autio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Pfrommer Fey</last_name>
      <phone>615-524-4110</phone>
      <email>julie.pfrommer@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Infante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN, MSN</last_name>
      <phone>210-593-5265</phone>
      <email>isabel.jimenez@start.stoh.com</email>
    </contact>
    <investigator>
      <last_name>Kyrakos Papadopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 31, 2014</lastchanged_date>
  <firstreceived_date>December 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Oncology</keyword>
  <keyword>Cancer</keyword>
  <keyword>Solid Tumors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
